Adding pharmacists to primary care teams reduces predicted long-term risk of cardiovascular events in Type2 diabetic patients without established cardiovascular disease: Results from a randomized trial

Diabetic Medicine

Volumn 29, Issue 11, 2012, Pages 1433-1439

  Ladhani, N N ^a   Majumdar, S R ^a   Johnson, J A ^a   Tsuyuki, R T ^a   Lewanczuk, R Z ^a   Spooner, R ^a   Simpson, S H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; GENERAL PRACTITIONER; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACIST; PRIMARY MEDICAL CARE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PATIENT CARE TEAM; PHARMACISTS; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84867220688     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03673.x     Document Type: Article

References (30)

1. Jansson SP, Andersson DK, Svardsudd K. Mortality trends in subjects with and without diabetes during 33years of follow-up. Diabetes Care 2010; 33: 551-556.
2. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368: 29-36.
3. Tan MH, MacLean DR. Epidemiology of diabetes mellitus in Canada. Clin Invest Med 1995; 18: 240-246.
4. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Vascular protection in people with diabetes. Can J Diabetes 2008; 32: S102-S106.
5. Ryden L, Standl E, Bartnik M, Van den BG, Betteridge J, de Boer MJ et al.Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
6. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type2 diabetes. N Engl J Med 2008; 358: 580-591.
7. Braga M, Casanova A, Teoh H, Dawson KC, Gerstein HC, Fitchett DH et al.Treatment gaps in the management of cardiovascular risk factors in patients with type2 diabetes in Canada. Can J Cardiol 2010; 26: 297-302.
8. Krass I, Hebing R, Mitchell B, Hughes J, Peterson G, Song YJ et al.Diabetes management in an Australian primary care population. J Clin Pharm Ther 2011; 36: 664-672.
9. Simpson SH, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, Spooner R, Johnson JA. Effect of adding pharmacists to primary care teams on blood pressure control in patients with type2 diabetes: a randomized controlled trial. Diabetes Care 2011; 34: 20-26.
10. Lee JD, Morrissey JR, Patel V. Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine). Curr Med Res Opin 2004; 20: 765-772.
11. Clifford RM, Davis WA, Batty KT, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2005; 28: 771-776.
12. Mendivil CO, Cortes E, Sierra ID, Ramirez A, Molano LM, Tovar LE et al.Reduction of global cardiovascular risk with nutritional versus nutritional plus physical activity intervention in Colombian adults. Eur J Cardiovasc Prev Rehabil 2006; 13: 947-955.
13. Taveira TH, Wu WC, Martin OJ, Schleinitz MD, Friedmann P, Sharma SC. Pharmacist-led cardiac risk reduction model. Prev Cardiol 2006; 9: 202-208.
14. Tuthill A, Quinn A, McColgan D, McKenna M, O'Shea D, McKenna TJ. A prospective randomized controlled trial of lifestyle intervention on quality of life and cardiovascular risk score in patients with obesity and type2 diabetes. Diabetes Obes Metab 2007; 9: 917-919.
15. Wister A, Loewen N, Kennedy-Symonds H, McGowan B, McCoy B, Singer J. One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk. CMAJ 2007; 177: 859-865.
16. El FF, Bruijnzeels MA, Uitewaal PJ, Frenken RA, Berg M, Hoes AW. Intensified preventive care to reduce cardiovascular risk in healthcare centres located in deprived neighbourhoods: a randomized controlled trial. Eur J Cardiovasc Prev Rehabil 2008; 15: 488-493.
17. Pirraglia PA, Taveira TH, Cohen LB, Wu WC. Effectiveness of a multifactorial cardiovascular risk reduction clinic for diabetes patients with depression. Prev Chronic Dis 2008; 5: A127.
18. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with Type2 diabetes mellitus. Br J Clin Pharmacol 2009; 67: 547-557.
19. Hemann BA, Bimson WF, Taylor AJ. The Framingham Risk Score: an appraisal of its benefits and limitations. Am Heart Hosp J 2007; 5: 91-96.
20. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006; 92: 1752-1759.
21. McEwan P, Williams JE, Griffiths JD, Bagust A, Peters JR, Hopkinson P et al.Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med 2004; 21: 318-323.
22. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type2 diabetes: results from a UK study. Diabet Med 2005; 22: 554-562.
23. Stevens RJ, Coleman RL, Holman RR. Framingham risk equations underestimate coronary heart disease risk in diabetes. Diabet Med 2005; 22: 228.
24. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in TypeII diabetes (UKPDS56). Clin Sci (Lond) 2001; 101: 671-679.
25. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
26. 2006 Community Profiles. Ottawa: Statistics Canada, 2007. Available at http://www12.statcan.ca/census-recensement/2006/dp-pd/prof/92-591/index.cfm?Lang=E Last accessed 5 December 2011.
27. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
28. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type2 diabetes: a prospective observational study (UKPDS75). Diabetologia 2006; 49: 1761-1769.
29. Chambless LE, Dobson AJ, Patterson CC, Raines B. On the use of a logistic risk score in predicting risk of coronary heart disease. Stat Med 1990; 9: 385-396.
30. Johnson JA, Eurich DT, Toth EL, Lewanczuk RZ, Lee TK, Majumdar SR. Generalizability and persistence of a multifaceted intervention for improving quality of care for rural patients with type2 diabetes. Diabetes Care 2005; 28: 783-788.